Skip to main content
. 2021 Sep 2;338:537–547. doi: 10.1016/j.jconrel.2021.08.061

Fig. 8.

Fig. 8

In vivo safety evaluation of PVES and PVES/mRNA vaccine. (A) Saline, PVES and PVES/mRNA (30 μg) were intramuscularly injected into mice at the dose of 180 μg for PVES. Cytokines in plasma were recorded at 6 h and 24 h post injection. (B) Body weight changes during the immune period. (C) H&E staining of liver, spleen, kidney pathology on 42 days post initial immunization. Scale bar, 200 μm.